Streetbeat News

Stock Prices

CHMI

CHMI-B preferred shares offer a 10.7% yield but are considered high-risk and overpriced. They are recommended only for trading, not long-term investment, due to a low common equity to preferred liquidation ratio.

Portfolio Pulse from

November 10, 2024 | 4:00 pm

VOO

The S&P 500 surged nearly 4% post-election due to bullish seasonality and dovish Fed signals, reaching new highs. Despite strong gains, VOO's high valuation and lower EPS estimates suggest a cautious hold rating. Positive fundamentals include robust Q4 GDP growth and potential corporate tax cuts, but risks like mass deportations and tariffs loom.

Portfolio Pulse from

November 10, 2024 | 4:00 pm

DOG

The ProShares Short Dow30 ETF (DOG) offers investors a way to profit from declines in the Dow Jones Industrial Average with -1x daily inverse exposure. It is suitable for short-term trades or hedges but not for long-term investments due to compounding effects. DOG has a low expense ratio of 0.95% and is less risky compared to leveraged inverse ETFs.

Portfolio Pulse from

November 10, 2024 | 4:00 pm

EVT

EVT offers a diversified portfolio with a focus on equities and fixed-income, favoring the financial sector. The fund's 7.85% distribution yield is primarily funded by capital gains, and potential Fed rate cuts could ease borrowing costs, increasing NII coverage.

Portfolio Pulse from

November 10, 2024 | 3:45 pm

IREN

Levi & Korsinsky has notified investors of Iris Energy Limited (NASDAQ:IREN) about a class action lawsuit. Investors who suffered losses can learn about potential recovery under federal securities laws.

Portfolio Pulse from

November 10, 2024 | 3:15 pm

AIXI

Levi & Korsinsky has notified investors of Xiao-I Corporation (NASDAQ:AIXI) about a class action lawsuit. Investors who suffered losses can learn about potential recovery under federal securities laws.

Portfolio Pulse from

November 10, 2024 | 3:15 pm

APGE

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis and other conditions, with upcoming Phase 2 results. The company's strong cash position and diverse pipeline support its valuation.

Portfolio Pulse from

November 10, 2024 | 3:15 pm

MNMD

Mind Medicine's stock price surged after a Q3 update confirmed unchanged clinical timelines. The market's bullish stance is also influenced by a competitor's recent difficulties, positioning Mind Medicine as a favored choice in the psychedelics sector.

Portfolio Pulse from

November 10, 2024 | 3:15 pm

VPU

The article discusses a recommended Vanguard ETF to buy with $500, highlighting its long-term appeal.

Portfolio Pulse from

November 10, 2024 | 3:00 pm

PFE

The article discusses the potential stock price movement of Pfizer (PFE) during Donald Trump's presidency, suggesting it is more likely to hit $22 before reaching $33.

Portfolio Pulse from

November 10, 2024 | 3:00 pm